The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The new company believes it can be the dominant clearinghouse for genome analysis apps or other tools, with free and unlimited storage of users' genomic data.
As many as 10,000 Nevadans will get free genetic testing through a large population health study being conducted by non-profit care network Renown Health.
Early backers can get their genome or exome sequenced at discounted rates of $999 and $399, respectively, limited to the first 10 and 50 users in each case.
The company has developed a panel of 15 genes, identified from scientific literature, that specifically link to an athlete's potential to respond to power or endurance training.
Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.
Portable's mobile app allows patients to capture genotype, phenotype, and other data, and potentially profit from sharing it with interested third parties.
Researchers from Brigham and Women's and Harvard surveyed more than 1,600 new customers of 23andMe or Pathway Genomics in the US, of whom 80 were adopted.
Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.
Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.
In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.
